Cargando…
Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
BACKGROUND: Tumour necrosis factor alpha (TNFα)‐antagonism effectively treats ulcerative colitis (UC). The golimumab clinical programme evaluated subcutaneous (SC) and intravenous (IV) induction, and SC maintenance regimens, in TNFα‐antagonist‐naïve patients with moderate‐to‐severe active UC despite...
Autores principales: | Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755132/ https://www.ncbi.nlm.nih.gov/pubmed/26119226 http://dx.doi.org/10.1111/apt.13291 |
Ejemplares similares
-
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
por: Gibson, Peter R, et al.
Publicado: (2016) -
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
por: Adedokun, Omoniyi J., et al.
Publicado: (2017) -
Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis
por: Sandborn, W. J., et al.
Publicado: (2016) -
Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
por: Jharap, B., et al.
Publicado: (2015) -
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence
por: Kruis, W., et al.
Publicado: (2017)